This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sunesis Pharmaceuticals Appoints Steve Carchedi To Board Of Directors

SOUTH SAN FRANCISCO, Calif., June 11, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Steve Carchedi has been appointed to the Sunesis Board of Directors, effective immediately.

Currently, Mr. Carchedi serves as the President, Commercial Operations for Mallinckrodt Specialty Pharmaceuticals, the Pharmaceuticals business of Covidien plc. Having held key positions at several leading multinational pharmaceutical companies, Mr. Carchedi brings more than 30 years of commercial industry experience focused in Oncology, Neurology, Urology, Endocrinology and Cardiology. Previously, he served as Chief Marketing Officer for General Electric (GE) Healthcare-MDx where he was responsible for leading worldwide marketing for GE's Medical Diagnostics business. Prior to joining GE Healthcare, Mr. Carchedi held senior commercial leadership positions at Endo Pharmaceuticals, Enzon Pharmaceuticals and McNeil Specialty Pharmaceuticals, a subsidiary of Johnson & Johnson. Mr. Carchedi also held the position of Global Marketing Leader for Johnson & Johnson Oncology, where he led the worldwide product launch of VELCADE® (bortezomib). Before joining Johnson & Johnson, Mr. Carchedi played a key role in commercializing a number of oncology products, including GEMZAR® (gemcitabine) at Eli Lilly & Company, as well as TAXOL® (paclitaxel) and PARAPLATIN® (carboplatin) at Bristol Myers Squibb.

"Steve's extensive experience in oncology drug development and commercialization will be invaluable to Sunesis as we prepare for our future commercial and regulatory milestones," stated Daniel Swisher, Chief Executive Officer of Sunesis. "We welcome Steve to our Board and look forward to his contributions as we advance the VALOR trial to completion and prepare the market for an anticipated launch of vosaroxin in AML."

"I am delighted to be joining the talented and dedicated team at Sunesis as a Board member," stated Mr. Carchedi. "Vosaroxin has transformative potential in the AML treatment landscape, and I look forward to sharing my expertise in helping commercialize this exciting oncology candidate and to contributing to the future growth of the company."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs